Applying Fusion Protein Technology to E. coli - Protein fusions are a leading option to produce difficult-to-express proteins, especially in Escherichia coli. - BioPharm International


Applying Fusion Protein Technology to E. coli
Protein fusions are a leading option to produce difficult-to-express proteins, especially in Escherichia coli.

BioPharm International

Size of the Fusion Tag

Table 4. The size of the fusion tag influences the yield of the purified protein.
The size of the fusion tag plays a crucial role in the overall yield of the purified protein. As seen in Table 4, the yield of the purified target protein is dictated by the yield of the fusion protein: the larger the fusion tag, the lesser the overall yield. Split SUMO, which is 47 amino acids long, is only 19% of the fusion when Split SUMO is fused to a target protein that is 200 amino acids in length (47/247). In contrast, NusA, which is 495 amino acids long, is 71% of the fusion with the same target protein (495/695). Therefore, if expression yielded one gram of fusion protein for both Split SUMO–Target and NusA–Target, the yield of the purified target after cleavage would be 0.810 g and 0.288 g, for Split SUMO and NusA, respectively.

Specificity, Efficiency, and Site of Cleavage

Table 5. Abbreviations
The quality, quantity, and activity of the purified protein are influenced by the specificity, efficiency, and site of cleavage. Cleavage of the fusion usually is necessary because the fusion interferes with the structural or functional properties of the recombinant protein.57 Fusions can be cleaved by either chemical or enzymatic strategies.58,59 These methods include the use of engineered cleavage sites that are recognized by the proteases and are positioned between the fusion tag and the protein target. Proteases that have been employed to cleave fusion tags include tobacco etch virus (Tev) protease,60 factor Xa, thrombin protease,59 and the SUMO protease.12–16 Problems associated with proteolytic cleavage of fusion tags are low yield, precipitation of the protein of interest, labor-intensive optimization of cleavage conditions, expense of proteases, failure to recover active, structurally intact protein,61 and the generation of non-native N-terminal amino acids (not the case with SUMO and ubiquitin fusions12–16 ). As a result, choosing the right chemical or enzymatic strategy is crucial for achieving active protein of high quality and quantity.

JOHN HALL is vice president of business development at LifeSensors, Inc., Malvern, PA, 610.644.8845 x 305,


1. Panlou AK, Reichert JM. Recombinant protein therapeutics-success rates, market trends and values to 2010. Nature Biotechnol. 2004; 12:1513–9.

2. Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 1990; 185:60–89.

3. Ikura K, Kokubu T, Natsuka S, Ichikawa A, Adachi M, Nishihara K, et al. Co-overexpression of folding modulators improves the solubility of the recombinant guinea pig liver transglutaminase in Escherichia coli. Prep. Biochem. Biotechnol. 2002; 32:189–205.

4. Smith DB, Johnson, KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988; 67:31–40.

5. Bedouelle H, Duplay P. Production in Escherichia coli and one-step purification of bifunctional hybrid proteins which bind maltose. Export of the Klenow polymerase into the periplasmic space. Eur. J. Biochem. 1988; 171:541–549.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here